Innovative training device optimizes Paralympian wheelchair use
The Center for Human Movement Sciences of the UMCG/UG, together with Lode BV, has developed a new wheelchair ergometer. This is a new technology that enables all wheelchair users, from early on in the rehabilitation process to Paralympic level sports, to train in their own wheelchair and be given feedback. The equipment enables the force exerted on each separate wheel to be measured. Detailed measurements can be taken on how the performance is achieved, thus enabling the propulsion method and fitness of the individual to be improved and the wheelchair further optimized. This can help prevent physical strain and generate better performance. The new ergometer is the first in the world of its kind.
More information
- Contact: via the UMCG Press Office, tel. 050 361 2200
- Riemer Vegter's PhD research
University of Groningen videos
The weekly online video magazine Unifocus highlights topics related to the University of Groningen in the fields of research and society, student life, teaching, policy and internationalization.
You can find more videos in our video portal.
Last modified: | 04 December 2020 2.13 p.m. |
More news
-
05 February 2021
Smoking during pregnancy affects the pulmonary health of future grandchildren
If a woman smokes during pregnancy, there is a higher risk that her future grandchildren will have lung problems and asthma. These are the findings of a study carried out by researchers at the University Medical Center Groningen (UMCG) among 37,000...
-
03 February 2021
Mental health at lowest ebb since the start of the coronavirus pandemic
Our quality of life is now the worst it has been since the start of the coronavirus pandemic: people in the Northern Netherlands currently give their life a score of 6.9. Last summer, this was 7.7 and at the start of the pandemic, it was 7.4. In...
-
26 January 2021
Study into the effect of COVID-19 vaccines in vulnerable groups
UMCG researchers to study the effect of COVID-19 vaccines on kidney, lung transplant and cancer patients. For this, they will be granted approx. 7.2 million Euro from ZonMw.